Differential Effects of Nebivolol and Metoprolol on Central Aortic Pressure and Left Ventricular Wall Thickness
Differential Effects of Nebivolol and Metoprolol on Central Aortic Pressure and Left Ventricular Wall Thickness
复制标题
DOI：
10.1161/hypertensionaha.110.155507
复制
发表时间：
2011-06-01
期刊：
影响因子：
8.3
通讯作者：
Eha, Jaan
中科院分区：
文献类型：
--
作者：
Kampus, Priit;Serg, Martin;Eha, Jaan
本研究的目的是研究血管舒张性β受体阻滞剂奈必洛尔和心脏选择性β受体阻滞剂琥珀酸美托洛尔对主动脉血压和左心室壁厚度的影响。我们对80例高血压患者进行了随机、双盲研究。患者每天接受5 mg奈必洛尔或50 - 100 mg琥珀酸美托洛尔治疗1年。在基线和研究结束时测量他们的心率、中心和肱动脉血压、平均动脉压、增强指数、颈动脉-股动脉脉搏波速度和左心室壁厚度。奈必洛尔和美托洛尔显著降低心率、肱动脉血压和平均动脉压的程度相同。然而，中心收缩压和舒张压、中心脉压和左心室壁厚度的降低仅在奈必洛尔组中具有显著性。左室间隔厚度变化与中心收缩压变化（r = 0.41; P = 0.001）和中心脉压变化（r = 0.32; P = 0.01）显著相关。在两个治疗组中均未检测到增强指数或颈动脉-股动脉脉搏波速度的显著变化。这项原理验证研究提供的证据表明，具有血管舒张特性的β受体阻滞剂在抗高血压治疗中可能优于传统β受体阻滞剂;然而，这仍有待在更大规模的试验中进行检验。（高血压。2011;57：1122-1128.）。在线补充资料
The aim of this study was to investigate the effects of the vasodilating beta-blocker nebivolol and the cardioselective beta-blocker metoprolol succinate on aortic blood pressure and left ventricular wall thickness. We conducted a randomized, double-blind study on 80 hypertensive patients. The patients received either 5 mg of nebivolol or 50 to 100 mg of metoprolol succinate daily for 1 year. Their heart rate, central and brachial blood pressures, mean arterial pressure, augmentation index, carotid-femoral pulse wave velocity, and left ventricular wall thickness were measured at baseline and at the end of the study. Nebivolol and metoprolol significantly reduced heart rate, brachial blood pressure, and mean arterial pressure to the same degree. However, reductions in central systolic and diastolic blood pressures, central pulse pressure, and left ventricular wall thickness were significant only in the nebivolol group. The change in left ventricular septal wall thickness was significantly correlated with central systolic blood pressure change (r = 0.41; P = 0.001) and with central pulse pressure change (r = 0.32; P = 0.01). No significant changes in augmentation index or carotid-femoral pulse wave velocity were detected in either treatment group. This proof-of-principle study provides evidence to suggest that beta-blockers with vasodilating properties may offer advantages over conventional beta-blockers in antihypertensive therapy; however, this remains to be tested in a larger trial. (Hypertension. 2011;57:1122-1128.). Online Data Supplement